Abeona Therapeutics Signs $20M M&A Deal with Ellodi Pharmaceuticals, L.P.
Abeona Therapeutics acquired substantially all assets related to APT-1011 (now ABO-801), a Phase 3-ready candidate for eosinophilic esophagitis, from Ellodi Pharmaceuticals. The deal was structured with $20 million in upfront equity consideration (4,494,383 shares) and no upfront cash, with Ellodi eligible for $30 million upon FDA approval and up to $30 million in sales milestones plus royalties.
- Value
- $20M
- Counterparty
- Ellodi Pharmaceuticals, L.P.
“The acquisition of ABO-801 is an important step in building Abeona into a diversified commercial-stage company with multiple opportunities for value inflection, adding an asset with substantial revenue potential in a rapidly growing disease.”
Vish Seshadri, Ph.D., Chief Executive Officer of Abeona Therapeutics